PMEF
NTLA icon

Point72 Middle East FZE’s Intellia Therapeutics NTLA Stock Holding History

Point72 Middle East FZE’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,241
Closed -$450K – 1759
2023
Q3 		$450K Buy
+14,241
New +$552K 0.01% 829
2023
Q1 		– Sell
-480
Closed -$16.7K – 2033
2022
Q4 		$16.7K Buy
+480
New +$22.8K ﹤0.01% 1671

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Middle East FZE's NTLA Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 14,241 shares — an estimated $450K sold.

Point72 Middle East FZE first reported a position in NTLA in Q4 2022 and held it in 2 quarters. The position peaked at $450K in Q3 2023. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 14,241 Intellia Therapeutics shares in Q4 2023, an estimated $450K.
  • Point72 Middle East FZE first reported a position in Intellia Therapeutics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Intellia Therapeutics position peaked at $450K in Q3 2023.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.